Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.32% | -123.08% | -46.86% | 31.94% | 5.30% |
| Total Depreciation and Amortization | -15.68% | -8.99% | -6.90% | -4.11% | -1.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.14% | 649.80% | -25.52% | -25.33% | -46.99% |
| Change in Net Operating Assets | -97.59% | 322.52% | 133.24% | -154.40% | 35.38% |
| Cash from Operations | -51.41% | -33.73% | -6.45% | 14.63% | -8.99% |
| Capital Expenditure | -260.66% | 72.40% | -1,281.25% | 82.22% | 53.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 863.08% | 68.55% | -467.94% | 89.47% | -126.48% |
| Cash from Investing | 846.72% | 68.61% | -473.53% | 89.44% | -122.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 49,437.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 100.00% | -100.10% | 72,116.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 64.31% | 6.59% | -54.66% | -129.87% | 340.36% |